Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 171 across all filing types
Latest filing 2026-02-06 Regulatory Filings
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled to approve audited financial results for a specific quarter and nine months period ending December 31, 2025. It references compliance with SEBI regulations and insider trading rules, and mentions the closure of the trading window. The document does not contain the financial results themselves but is an announcement of the meeting where such results will be approved. The document length is short (1972 characters), and it serves as an intimation or notice rather than the actual financial report. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than a full financial report or earnings release.
2026-02-06 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a query about segment disclosure in the audited financial results for the quarter and half year ended September 30, 2025. It clarifies the company's position on segment reporting under Ind AS 108 and explains why segment-wise disclosure was not included in the submitted consolidated financial results. The document does not contain actual financial statements or detailed financial data but is a regulatory clarification or response to an exchange query. The length is short (2511 characters), and it serves as a regulatory communication rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and clarifications that do not fit other specific categories.
2026-01-23 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Regulatory Filings Classification · 100% confidence The document is an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It discloses receipt of a Show-Cause Notice from a government tax authority regarding GST-related issues and potential financial implications. The document is addressed to stock exchanges and is a regulatory disclosure about a legal/tax matter, not a full report or financial statement. It does not contain financial statements or detailed financial analysis but is a compliance announcement about a regulatory/legal event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming that the regulation is not applicable as all securities are held in dematerialized form and no requests for dematerialization or cancellation were received for the quarter ended December 31, 2025. It is addressed to stock exchanges and is a compliance certificate from the Registrar and Share Transfer Agent. The document is short (2985 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a compliance-related certificate under SEBI regulations.
2026-01-07 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs the stock exchanges about the receipt of an order from a tax authority (Assistant Commissioner of CGST & Central Excise) regarding a GST-related demand and penalty. The document includes details of the order, the alleged violation, the financial impact, and the company's intended course of action. It is a regulatory announcement about a legal/regulatory matter affecting the company, not a full report or financial statement. The document is about disclosure of material regulatory communication as required by listing regulations, which fits best under Regulatory Filings (RNS). The document length is about 4992 characters, and it is not a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2025-12-26 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for insiders ahead of the financial results announcement for the quarter and nine months ended December 31, 2025. It references compliance with SEBI (Prohibition of Insider Trading) Regulations and the company's code of conduct. The document is short (1677 characters) and serves as a notification rather than containing any financial data or report. It does not contain financial statements or detailed analysis, nor does it announce or attach any report. Therefore, it is an announcement related to regulatory compliance and trading restrictions, which fits best under Regulatory Filings (RNS).
2025-12-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.